Poster Presentation Details

-0- *T TitleNovel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour ToxicityDate and timeWednesday, December 10, 2025, 08:00 (GMT)Poster number309PLocationThe Churchill Room, Queen Elizabeth II Centre, London*T

Bispecific TCE Overview

For the selected target, LabGenius has developed a selectivity-enhanced TCE. The company's lead optimisation platform, EVA?,was used to discover and concomitantly optimise a TCE with improved killing selectivity, potency, efficacy, and manufacturability. The biological mechanism underlying this enhanced selectivity is based on the principle of avidity. By harnessing avidity-driven selectivity, the optimised TCE can distinguish between healthy and diseased cells based on differential tumour-associated antigen expression.

About LabGenius Therapeutics

LabGenius Therapeutics is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company's discovery platform, EVA?, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. LabGenius Therapeutics operates a hybrid business model that includes partnering with biotech and pharmaceutical companies in parallel with pursuing a wholly-owned therapeutic pipeline. For more information, please visit www.labgeniustx.com, or connect on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251112292702/en/

Contact

Media: [email protected] Corporate / business development: [email protected]

© 2025 Business Wire, Inc.Disclaimer:This press release is not a document produced by AFP. AFP shall not bear responsibility for its content. In case you have any questions about this press release, please refer to the contact person/entity mentioned in the text of the press release.